Copy

Click here if you cannot read this message

  Press Release November 2014  
 
 
 

Bone Therapeutics Appoints Dr Guy Heynen as Chief Clinical and Regulatory Officer

Gosselies, Belgium, 24 November 2014 - BONE THERAPEUTICS, the regenerative therapy company addressing unmet medical needs in the fields of bone diseases and orthopaedics, today announces the appointment of Dr Guy Heynen as Chief Clinical and Regulatory Officer.  Dr Heynen will support Bone Therapeutics as it progresses its strong pipeline of regenerative bone disease and orthopaedic therapies through clinical development towards commercialisation.
 
Dr Heynen is a specialist in rheumatology and immunology, with extensive experience both in university medical practice and in the pharmaceutical industry. He has over 35 years’ experience in medical and regulatory affairs at local, regional and international levels and has a particular focus on management, team building and leadership. The majority of his career has been with Pfizer Inc., where he held a number of senior roles including Medical Director for Pfizer Switzerland, European Team Leader for the Alzheimer’s disease drug, Aricept, and Medical Team Leader for Pfizer’s anti-inflammatory drug franchise based in New York.
 
Dr Heynen also serves on the Boards of Euroscreen SA, Progenosis SA and as an advisor for Promethera Biosciences, roles which highlight his expertise and strong network in cell therapy. Dr Heynen remains a Regional Medical Monitor for Pfizer GmbH.
 
Dr Heynen started his career at the Belgian National Foundation for Research and in research roles at University Hospital, Liege, Belgium where he received his degree in medicine and rheumatology.
 
Enrico Bastianelli, CEO of Bone Therapeutics commented, “Guy Heynen has a distinguished track record both in hospital medical practice and industry. His understanding of clinical operations and regulatory affairs will be an invaluable asset to Bone Therapeutics as we move forward to advance our innovative late-stage pipeline of regenerative medicines in bone diseases and orthopaedics. His long-standing experience within major pharmaceutical companies around the world will be key in preparing to bring our products to market and supporting Bone Therapeutics’ development on a global scale. Dr Heynen’s experience advising cell therapy companies also provides important understanding of this growing sector.”
 
Dr Guy Heynen, commented: “Bone Therapeutics is at the forefront of developing some of the most promising therapies for bone disease and orthopaedic medicine. I am privileged to be joining the Company at such an exciting time in its development and I look forward to working with the team to advance its innovative products towards commercialisation.

-Ends-

 
 
 
 
 

Press Releases & News

November 2014

Bone Therapeutics and Kasios to collaborate on novel product for the optimisation of spinal fusion procedures

Read

 
 

 
 

For further information, please contact:

Bone Therapeutics SA

Tel: +32 (0)2 529 59 90
Enrico Bastianelli, Chief Executive Officer
Wim Goemaere, Chief Financial Officer
info@bonetherapeutics.com

Consilium Strategic Communications

Amber Bielecka, Mary-Jane Elliott,
Jessica Hodgson and Lindsey Neville
Tel: +44 (0) 20 3709 5708
bonetherapeutics@consilium-comms.com

 
 

 
 
Follow us

Click here to unsubscribe
 
 
 
 

About Bone Therapeutics

Bone Therapeutics is a leading biotechnology company specializing in the development of innovative regenerative therapies for the treatment of orthopaedic conditions. The current standard of care in this field involves major surgeries and long recovery periods. To overcome these problems, Bone Therapeutics is developing a range of innovative products containing regenerative osteoblastic/bone forming cells, administrable via a minimally invasive percutaneous technique; a unique proposition in the market.
PREOB®, Bone Therapeutics’ autologous cell product, is currently in pivotal Phase III clinical studies for two indications: osteonecrosis and non-union fractures, and in Phase II for treatment resistant osteoporosis.
ALLOB®, its allogeneic cell product, is in Phase II for the treatment of delayed union fractures and lumbar fusion for degenerative disease of the spine. The Company also runs preclinical research programs and develops product candidates.

Founded in 2006, Bone Therapeutics is headquartered in Gosselies (South of Brussels, Belgium). Bone Therapeutics’ regenerative products are manufactured to the highest GMP standards and are protected by a rich IP estate covering 9 patent families. Further information is available at www.bonetherapeutics.com
 


Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

 
Bone Therapeutics S.A. • Rue Adrienne Bolland, 8 • 6041 Gosselies • Belgium (Europe) • Phone: +32 (0) 2 529 59 90 • Fax: +32 (0) 2 529 59 93 • www.bonetherapeutics.com